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     INTRODUCTION 
  Antibiotic use is common among pediatric and adult 
patients presenting in both inpatient and outpatient set-
tings.  1   The scope and magnitude of antibiotic use is not 
well defined, particularly in low and middle income nations 
where antibiotics are often available without prescription. 
Antibiotic pre-treatment decreases the already low sensitiv-
ity of blood culture for detecting bacterial causes of pneu-
monia and sepsis in adults  2   and children.  3,  4   However, no 
studies have quantified the impact of antibiotic use on the 
recovery of specific bacterial pathogens and more impor-
tantly its impact on population-level incidence estimates for 
individual diseases such as those caused by   Streptococcus 
pneumoniae . 
  The World Health Organization (WHO) recommends that 
all countries prioritize the inclusion of the heptavalent pneu-
mococcal conjugate vaccine (PCV7) in national vaccine pro-
grams.  5   Countries considering vaccine introduction often 
use invasive pneumococcal disease (IPD) incidence esti-
mates as the primary indicator of disease burden, because 
accurate measures of other forms of pneumococcal disease 
(e.g., pneumonia) are difficult to obtain outside of vaccine 
probe studies. Accurate IPD estimates are therefore of crit-
ical public health importance and the impact of antibiotic 
use on these estimates is unknown. Using active, population-
based surveillance from two provinces in rural Thailand, we 
measured the prevalence of antibiotic use before blood cul-
ture and its impact on   S. pneumoniae   isolation and on esti-
mates of the incidence of pneumococcal bacteremia requiring 
hospitalization. 
   MATERIALS AND  METHODS 
  Setting.     The International Emerging Infections Program 
(IEIP), a collaboration between the Thailand Ministry of 
Public Health and the U.S. Centers for Disease Control and 
Prevention (CDC), has conducted an active, population-based 
surveillance for pneumonia requiring hospitalization since 
2002 in two rural provinces: Nakhon Phanom (population 
734,000), on the border of Laos in northeastern Thailand, and 
Sa Kaeo (population 526,000), adjacent to Cambodia in eastern 
Thailand.  6   Since May 2005, IEIP has also conducted enhanced 
surveillance for bacteremia requiring hospitalization in these 
same provinces.  7   Surveillance is conducted at all hospitals 
in the two provinces: 16 community (local) and 2 military 
hospitals (10 to 140 inpatient beds) and both provincial 
(referral) hospitals (225 and 327 inpatient beds). 
  Clinicians requested blood cultures from hospitalized 
patients as clinically indicated. Cultures were actively encour-
aged in all patients admitted with suspected pneumonia and 
patients < 5 years of age with suspected sepsis. To minimize 
potential confounding from patients with multiple blood cul-
tures, data were limited to cultures performed at least 7 days 
apart (i.e., repeat cultures within 7 days were excluded); cul-
tures obtained from the same patient ≥ 7 days apart were 
treated as unique patient encounters. Detailed clinical and 
demographic information were available for the subset of 
patients with blood cultures who were also captured in the 
pneumonia surveillance system,  7   whereas more limited data 
were available for other patients with blood cultures. 
   Antibiotic  use.     Reported antibiotic use before blood culture 
was defined as antibiotics received within 72 hours before 
culture based on patient report and the nurse’s review of 
medications received at the hospital. The name(s) of antibiotics 
received were determined by patient report or record review. 
The likely route of antibiotic administration (oral versus 
intravenous [IV] or intramuscular [IM]) was classified by a Thai 
physician (S.T.) based on usual hospital practice in Thailand. 
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  Pre-culture antibiotic use was also assessed by measuring 
serum antimicrobial activity using a serum disc assay. At the 
time of blood collection, a filter paper disc was coated with 
20 μL of patient serum and stored at −70°C. For testing, the fil-
ter paper was placed onto a Mueller-Hinton agar plate inocu-
lated with antibiotic-sensitive   Staphylococcus aureus   (ATCC 
9144). After 24 hours incubation at 35–37°C, growth inhibition 
around the disc was considered evidence of serum antimicro-
bial activity.  4  An additional measure of antibiotic exposure was 
created that defined antibiotic use as either reported antibiotic 
use or serum antimicrobial activity; this group was compared 
with patients who had no antibiotic use by either measure. 
   Blood  cultures.     Detailed methods have been described 
previously.  7,  8   Briefly, each blood specimen was divided into 
a bottle optimized for aerobic growth and into a bottle for 
enhanced growth of mycobacteria, with the goal of inoculating 
at least 10 mL from adults and 4 mL from children < 5 years of 
age into the aerobic bottle and the remainder into the anaerobic 
bottle. All blood cultures were processed at the two provincial 
hospital laboratories. Cultures collected at community 
hospitals were maintained at 15–30°C and transported within 
24 hours to the provincial hospitals. Cultures were processed 
using the BacT/ALERT 3D (bioMerieux, Hazelwood, MO) 
automated microbial detection system. Media from bottles 
with evidence of growth as signaled by the automated culture 
system (i.e., alarm-positive cultures) were sub-cultured using 
standard methods.  9   A pre-defined list of common contaminant 
species was used to determine if a given isolate was a likely 
pathogen. Confirmatory identification of   Streptococcus 
pneumoniae   was performed at the reference laboratory of the 
Thailand Ministry of Public Health and CDC. 
   Statistical  analysis.    Pearson’s  χ  2   tests of association were 
used to compare clinical characteristics (e.g., fever and 
respiratory symptoms) by antibiotic use. Agreement between 
reported antibiotic use and serum disc testing results was 
assessed using Kappa statistics. The χ  2   analyses were also used 
to test associations between antibiotic use and four blood 
culture endpoints: 1) alarm-positive by automated culture 
machine; 2) organism isolation; 3) pathogen (i.e., non-
contaminant) isolation; and 4)   S. pneumoniae   isolation. For 
comparison, isolation rates of  Escherichia coli  and  Burkholderia 
psuedomallei   were examined, expecting the former to be 
inhibited by antimicrobial activity and the latter to be largely 
unaffected. 
  Age group-specific pneumococcal bacteremia incidence 
rates were calculated by dividing the number of cases by per-
son-years under observation using corresponding popula-
tion estimates from Thailand’s National Economic and Social 
Development Board.  6   A Poisson distribution was assumed to 
calculate 95% confidence intervals (CI). To estimate adjusted 
incidence rates that accounted for cases missed because of 
pre-culture antibiotic use, the   S. pneumoniae   isolation rate in 
patients without antibiotic use was applied to the total number 
of blood cultures. Differences between observed and adjusted 
incidence rates were considered statistically significant when 
the point estimate for the adjusted rate fell outside the range 
of the 95% CI around the observed rate. Analyses were con-
ducted using SAS version 9.1 (Cary, NC) and SPSS version 
15.0 (Chicago, IL). 
   Ethical  considerations.     These data were collected as part of 
the public health surveillance activities, which were determined 
not to require institutional review board review. 
    RESULTS 
  From November 2005 through June 2008, 35,639 blood cul-
tures from 29,883 patients met our criteria for analysis; 6,114 
(17%) cultures came from patients who had 2 or more cul-
tures separated by ≥ 7 days. Among patients with > 1 culture, 
the median time between cultures was 106 days (interquartile 
range: 33–242 days). Antibiotic use in the 72 hours before 
blood culture was reported for 9,726 (27%) of 35,639 patient 
cultures. Similarly, 5,782 (24% of 24,538) blood cultures were 
from patients with serum antimicrobial activity. Antibiotic 
use, both reported and by serum antimicrobial activity, dif-
fered slightly by province and hospital size (  Table 1  ). Among 
patients with serum testing, the prevalence of antimicrobial 
activity increased with age. Serum antimicrobial activity test-
ing was often not performed for patients with small blood vol-
umes collected (e.g., very young children); as a result, patients 
with serum disc testing results were older on average than 
those without testing. According to both measures, antibiotic 
use before blood culture was highest in 2005 and significantly 
lower each year afterward, (  P   < 0.05). 
      Detailed  information  was  available  for  19,838  patients 
included in the pneumonia surveillance system. Among 
these patients, reported antibiotic use prevalence was 28%, 
and the median age was 29 years. Compared with patients 
without reported pre-culture antibiotic use, those with anti-
biotic use were more likely to have fever (38% versus 36%, 
  P   = 0.03), respiratory symptoms (83% versus 80%,   P   < 0.01), 
and require supplemental oxygen or intubation (31% versus 
29%,   P   < 0.01). The case-fatality proportion was also higher 
among patients with antibiotic use (4.6% versus 3.5%,   P   < 0.01). 
Human immunodeficiency virus (HIV) status was available 
for 5,523 (15.5%) of 35,642 patient cultures; HIV-positive 
  Table  1 
    Antibiotic use before blood culture defined by reported use  *   and 
by serum antimicrobial activity; Sa Kaeo and Nakhon Phanom, 
Thailand, November 2005 to June 2008   
Reported antibiotic use
Serum antimicrobial 
activity
Total % Yes Total % Yes
Total 35639 27.3 24538 23.6
Province
 Sa  Kaeo 13070 26.5 10208 24.4
 Nakhon  Phanom 22569 27.7 14330 23.0
Hospital Type
 Provincial  (  N   = 2) 15797 25.5 9208 25.6
 Community  (  N   = 18) 19842 28.7 15330 22.3
Age in years
  Less than 5 10719 26.3 3845 14.4
  5 to 19 3904 29.4 2468 17.5
  20 to 49 6939 28.9 6073 24.0
  50 to 64 5810 27.5 5069 26.0
  65 and greater 8267 26.2 7083 28.5
  Median age, years 35.3 49.0
Year † 
 2005 1502 33.9 1176 27.1
 2006 12213 30.9 8958 25.6
 2007 14757 25.9 9654 21.4
 2008 7167 22.8 4750 23.1
    *      Antibiotics received within 72 hours before culture based on patient report and the 
nurse’s review of hospital medications.   
    †      The year 2005 included only November and December. The year 2008 included January 
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patients had similar rates of pre-culture antibiotic use as HIV-
negative patients (28% versus 29%,   P   = 0.33). 
  Antibiotic names were available for 82% (8,004) of patients 
with reported antibiotic use. The most commonly reported 
drugs used were third generation cephalosporins (38%) and 
penicillin/penicillin derivatives (34%), both in monotherapy 
or in combination; 1,742 (22%) received ≥ 2 antibiotics. We 
could determine the likely mode of antibiotic administration 
for 6,368 (84% of 9,746 with reported antibiotic use); of those, 
50% (3,148) had only antibiotics typically administered orally 
and 50% (3,218) had at least one IM or IV antibiotic. 
  Correlation between serum antimicrobial activity and 
reported antibiotic use was moderate. After excluding patients 
missing antibiotic use data by either measure, 16% of patients 
were positive for antibiotic by both measures, 62% negative 
by both, and 23% discordant (Kappa = 0.42). Correlation 
increased slightly when reported antibiotics were limited to 
those administered IM or IV (Kappa = 0.48). Correlation was 
higher for patients aged 5 years and older (0.45) than for chil-
dren less than 5 years of age (0.27). The major source of dis-
cordance, particularly in young children, was negative serum 
antimicrobial disc testing among patients with reported anti-
biotic  use  ( Table  2      ). 
 Blood culture yields were significantly lower among patients 
with pre-culture antibiotic use compared with those without 
antibiotic use (  Table 3  ). This was true when the culture end-
point was alarm positivity, organism isolation, or pathogen iso-
lation, and regardless of whether pre-culture antibiotic use was 
determined by reported use, serum disc testing, or a combina-
tion of the two measures. Overall,   E. coli   was isolated more 
commonly from those without antibiotic use compared with 
those with pre-culture antibiotics. In contrast,   B. pseudomallei  
yield was higher among patients with pre-culture antibiotic 
use compared with those without antibiotic use.   Streptococcus 
pneumoniae   was isolated more often in patients without anti-
biotics regardless of whether antibiotic use was determined by 
reported use, serum disc testing, or a combination of the two 
measures. 
      When  analyses  were  limited  to  children  < 5 years of age, 
trends in culture yields for both antibiotic use measures were 
similar but not statistically significant for pathogen isolation. 
None of the 554 children < 5 years of age with serum antimi-
crobial activity had a positive blood culture for   S. pneumoniae , 
compared with 12 (0.4%) of 3,291 without serum antimicro-
bial activity (  P   = 0.09). Unexpectedly,   E. coli   isolation rates 
were higher among children < 5 years of age with positive 
serum disc testing (0.9%,   N   = 5; all < 1 year of age) compared 
with negative serum disc tests (0.2%;   N   = 5). 
  Culture yield, as measured by alarm positivity, organism iso-
lation, and pathogen isolation, including  S. pneumoniae , was sig-
nificantly lower among children < 5 years of age compared with 
older patients (  P   < 0.05 for all), which may have been caused 
by lower blood volumes available for culture in children. Less 
than half (45%) of children < 5 years of age had the target 4 
mL available for blood culture and 27.7% had less than 2 mL. 
  Streptococcus pneumoniae   yield was lowest among children 
< 5 years of age with < 2 mL collected compared with those 
with 2–3.99 mL collected and 4 mL or more: 0.1% ( N  = 4), 0.2% 
(  N   = 7), and 0.3% (  N   = 13), respectively.   Streptococcus pneumo-
niae   yield within blood volume strata among children < 5 years 
of age indicated non-significant reductions associated with pre-
culture antibiotics, although these analyses are limited by small 
numbers: no   S. pneumoniae   isolated for both positive and nega-
tive serum antimicrobial activity with < 2 mL; 0 (serum antimi-
crobial activity) versus 0.4% (no serum antimicrobial activity) 
for 2–3.99 mL; and 0 versus 0.4% for 4 mL or more. 
  Figure 1 illustrates the potential impact of pre-culture 
antibiotic use on age-specific incidence rates of hospitalized 
  Table  2 
    Correlation between reported antibiotic use and serum antimicrobial 
activity by disc testing among patients < 5 years of age  *     
Total
Reported antibiotic use  † 
Yes No Not sure
Serum disc result   N   (%) n (%) n (%) n (%)
Positive 554 (14) 348 (31) 195 (8) 11 (5)
Negative 3291 (86) 778 (69) 2281 (92) 232 (96)
Total 3845 ‡  1126 2476 243
    *     Kappa = 0.27 (analysis excluded “not sure” reported antibiotic use).   
    †      Antibiotics received within 72 hours before culture based on patient report and the 
nurse’s review of hospital medications.   
    ‡     Serum disc testing was performed for 36% (3,845/10,719) of cultures in children < 5 years 
of age.   
  Table  3 
    Blood culture outcomes by reported antibiotic use, serum antimicrobial activity, and a combination of measures, Sa Kaeo and Nakhon Phanom, 
Thailand, November 2005 to June 2008   
Total
Reported antibiotic use  *  Serum antimicrobial activity  † 
Combined – reported antibiotic use 
and serum antimicrobial activity  ‡ 
Yes No
  P   value
Yes No
  P   value
Yes by either No by both
  P   value   N   = 35639   N   = 9726   N   = 22462   N   = 5782   N   = 18756   N   = 11949   N   = 13997
Alarm positive culture  §  5393 (15.1)  ¶  1099 (11.3) 3806 (16.9)   P   < 0.01 656 (11.3) 3255 (17.4)   P   < 0.01 1404 (11.7) 2577 (18.4)   P   < 0.01
Organism isolation 4729 (13.3) 910 (9.4) 3387 (15.1)   P   < 0.01 521 (9.0) 2857 (15.2)   P   < 0.01 1164 (9.7) 2282 (16.3)   P   < 0.01
Pathogen isolation  ||  2419 (6.8) 393 (4.0) 1813 (8.1)   P   < 0.01 252 (4.4) 1650 (8.8)   P   < 0.01 529 (4.4) 1343 (9.6)   P   < 0.01
  Escherichia coli  843 (2.4) 92 (0.95) 675 (3.0)   P   < 0.01 81 (1.4) 633 (3.4)   P   < 0.01 139 (1.3) 545 (3.9)   P   < 0.01
  Burkholderia 
pseudomallei  321 (0.90) 105 (1.1) 186 (0.83)   P   = 0.03 92 (1.6) 173 (0.93)   P   < 0.01 148 (1.2) 117 (0.8)   P   < 0.01
  Streptococcus 
pneumoniae  109 (0.31) 9 (0.09) 83 (0.37)   P   < 0.01 3 (0.05) 84 (0.45)   P   < 0.01 12 (0.10) 68 (0.49)   P   < 0.01
    *      Antibiotics received within 72 hours before culture based on patient report and the nurse’s review of hospital medications.   P   values reflect row-wise comparisons of “Yes” vs. “No” reported 
antibiotic use; “Not Sure” excluded,   N   = 3451.   
  †     P   values reflect row-wise comparisons of “Yes” vs. “No” serum antimicrobial activity; “Missing” excluded,   N   = 11101.   
  ‡     P   values reflect row-wise comparisons of “Yes by either” vs. “No by both,” “Unknown” excluded, (  N   = 9693). The “Unknown” category includes: 1) patients with “no” reported antibiotic use 
and “missing” serum antimicrobial activity, 2) patients with “unsure” reported antibiotic use and “negative” serum antimicrobial activity, and 3) “unsure” reported antibiotic use and “missing” 
serum antimicrobial activity.   
    §     BacT/ALERT machine alarmed signaling a positive culture.   
  ¶   Parentheses  show  column  percentages.  
  ||     Non-contaminant species isolated from subculture.   304 RHODES AND OTHERS
pneumococcal bacteremia. The adjusted incidence rates were 
significantly greater than the overall observed rate (3.2 per 
100,000 person-years; 95% CI = 2.7, 3.9), 60% higher when 
adjusted for antibiotic use defined as reported use or serum 
antimicrobial activity (5.1 per 100,000). The adjusted rates 
within each age category were similar across methods of defin-
ing antibiotic exposure, except for young children. Among 
children < 5 years of age, the adjusted incidence was 63% 
higher when antibiotic use was defined by serum antimicrobial 
activity (17.9 versus 11.0 per 100,000 person-years [95% CI for 
observed incidence = 7.0, 16.3]), 9.6% higher when adjusted 
for reported antibiotic use, and 18% higher when adjusted for 
antibiotic exposure defined as either reported use or serum 
antimicrobial activity. When limited to children < 5 years of 
age with the targeted 4 mL blood volume, incidence was 40% 
higher after adjustment for serum antimicrobial activity: 13.0 
versus 18.2 per 100,000 person-years. 
   DISCUSSION 
  This investigation used data from active, population-based 
surveillance for bacteremia and pneumonia to document high 
rates of pre-culture antibiotic use and show that the frequency 
of  S. pneumoniae  isolation in patients with reported pre-culture 
antibiotic use was one-fourth that in those without reported 
use. Differences in   S. pneumoniae   isolation were even greater 
when antibiotic use was defined by serum antimicrobial activ-
ity or by a combined measure of reported use or serum activ-
ity. This lower culture yield significantly reduced the estimated 
incidence of pneumococcal bacteremia overall and in children 
< 5 years of age, by 32% and 39%, respectively, when antibiotic 
use was defined by serum antimicrobial activity. 
  Our findings were consistent across numerous culture end-
points (alarm positivity, overall isolate yield, and pathogen 
yield); however, consistent with its fastidious nature,   S. pneu-
moniae  isolation was affected to a greater degree by pre-culture 
antibiotic use than pathogen yield overall. These observations 
are in line with previous studies showing the effects of pre-
culture antibiotic use.  2,  4,  10,  11   To further examine internal con-
sistency,   E. coli   was chosen as a positive control, because it is 
a frequently cultured organism with known susceptibility to 
commonly used antibiotics.  12   As expected, pre-culture antibi-
otic use significantly reduced   E. coli   yield overall. However, 
among children < 5 years of age,   E. coli   isolation was higher 
in patients with pre-culture antibiotic use, an unexpected find-
ing driven by   E. coli   sepsis cases in young infants who were 
likely treated empirically before culture collection. In contrast, 
  B. pseudomallei  , an organism endemic in rural Thailand and 
refractory to one-time   in vivo   antibiotic treatment,  13   was cho-
sen as a negative control.   B. pseudomallei   recovery was actually 
higher among those with pre-culture antibiotic use, which may 
have resulted from patients with more severe disease being 
both more likely to receive antibiotics early and to have posi-
tive cultures. Overall, these findings strengthen the conclusion 
that differences in culture yield for   S. pneumoniae   by antibiotic 
use were caused by the antibiotic exposure and not to other fac-
tors, such as the amount of specimen collected or HIV status.  4   
  Our pre-culture antibiotic use rates (by serum antimicrobial 
activity) of 24% overall and 14% among children < 5 years of 
age compare with those of two Kenya studies showing urine 
antimicrobial activity in ~50% of adults  2   and serum activ-
ity ~10% in children  4   evaluated for possible sepsis. The high 
prevalence of pre-culture antibiotic use in our study did not 
result solely from pre-hospital antibiotic use. The large frac-
tion of IM and IV antibiotics used suggests antibiotics are 
often administered in the emergency room and/or medical 
wards before blood cultures are obtained. Pre-culture antibi-
otic administration in health-care settings may be an under-
appreciated cause of false-negative blood cultures, especially 
in areas where access to modern blood culture systems has 
recently been expanded. From 2005 to 2008 the prevalence 
of pre-culture antibiotics decreased significantly in our sur-
veillance population (  Table 1  ), possibly related to education 
emphasizing the importance of culture collection before anti-
biotic administration. Nonetheless, the magnitude and scope 
of pre-culture antibiotic use, both in and outside health-care 
settings, merits further attention in Thailand and in similar set-
tings where antibiotics are available without prescription and 
bacterial culture-based methods of measuring disease inci-
dence are in place. 
  This study benefited from the use of two measures of anti-
biotic use: reported use (based on patient report and nursing 
records) and serum antimicrobial activity. Although neither 
measure of antibiotic use is a true gold standard, we found 
consistent and significant associations across multiple cul-
ture endpoints. We found moderate agreement between the 
two measures with slightly better agreement among patients 
receiving IM/IV antibiotics and patients 5 years of age and 
older. Lack of agreement between measurements may have 
resulted from poor patient recall and/or serum antibiotic lev-
els too low for detection. Testing urine may have been more 
sensitive than testing serum to detect antimicrobial activity, 
but urine is difficult to collect on demand at the time of blood 
culture, especially in children. Poorer correlation in patients 
< 5 years of age may have been caused by increased misclas-
sification of the reported antibiotic use measure, because chil-
dren taking antibiotics often miss doses (or do not receive 
full doses), and non-antimicrobial drugs may get reported as 
antibiotics. For these reasons, we believe that serum antimi-
crobial activity serves as the most accurate measure of pre-
culture antibiotic use and should be the primary measure used 
to adjust pneumococcal disease incidence rates for children 
< 5 years of age (  Figure 1  ). 
  Our investigation would have benefited from additional data 
describing the context of antibiotic use (i.e., pharmacy, out-
patient clinic, emergency department, or hospital ward). The 
analysis also relied on blood cultures collected at clinicians’ 
discretion as opposed to standardized enrollment, limiting 
comparisons to other clinical settings where culture practices 
may differ. As another limitation, we were unable to stratify 
the impact of pre-culture antibiotics by degree of anti-pneu-
mococcal activity. All   S. pneumoniae   isolates were sensitive to 
penicillin,  8   and too few patients reported taking antibiotics to 
which non-susceptibility rates were high (e.g., co-trimoxazole), 
making it difficult to compare the effects of individual antibiot-
ics. Low blood volume also substantially reduced culture yield, 
and we were unable to fully separate the effects of pre-culture 
antibiotic use and blood volume in young children because of 
small numbers. However, there is no reason to think that the 
microbiological effects of pre-culture antibiotics on culture 
yield would differ among young children. It should also be 
noted that our analytic approach assumed that, if not for anti-
biotics, culture yields would be the same among patients with 
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captured by the pneumonia surveillance system, individuals 
with reported pre-culture antibiotics had similar clinical char-
acteristics to those without antibiotics, supporting this assump-
tion. Finally, the generalizability of our findings may be limited 
because the impact of pre-culture antibiotic use will vary with 
local antibiotic use, antibiotic classes used, and pneumococcal 
susceptibility patterns. However, nonjudicious antibiotic use is 
common in other parts of Thailand  14   and Southeast Asia  15   and 
other regions of the world  16   and the impact might be expected 
to be at least as substantial as what we observed. 
  The illustration of observed and adjusted pneumococcal 
bacteremia incidence (  Figure 1  ) is not intended as a defini-
tive estimate of invasive pneumococcal disease incidence in 
Thailand. A more complete analysis of pneumococcal disease 
burden in Thailand was published previously  8   and found rates 
of bacteremia requiring hospitalization (10.6–28.9 cases per 
100,000 in children < 5 years of age) near pre-vaccine rates 
in the United States and other countries where pneumococ-
cal conjugate vaccine has been introduced. Although our sur-
veillance did not allow us to quantify the effect of pre-culture 
antibiotic use on overall IPD incidence estimates (both non-
hospitalized bacteremia cases as well as IPD cases confirmed 
by culture of other normally sterile sites are not captured), it is 
reasonable to conclude that the impact would be similar. 
  In this study, we described pre-culture antibiotic use in rural 
Thailand, which has not been detailed for Thailand or other 
Southeast Asian countries. We showed that pre-culture antibi-
otics are associated with significantly lower culture yields for 
  S. pneumoniae  . These findings underscore the limitations of 
exclusively culture-based methods to estimate   S. pneumoniae  
bacteremia and IPD incidence. Our findings are also directly 
relevant to pneumococcal disease cost estimation and cost-
effectiveness analyses of pneumococcal vaccine.  17,  18  Alternative 
methods for detecting   S. pneumoniae  , such as antigen detec-
tion  19   or molecular assays,  20   should be evaluated in epidemi-
ologic studies and clinical settings for their ability to detect 
pneumococcal disease in patients pre-treated with antibiotics. 
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